Patents by Inventor Robert M. Raleigh

Robert M. Raleigh has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10806743
    Abstract: Disclosed herein are formulations comprising lactitol for the treatment of chronic idiopathic constipation. As disclosed herein, the formulations are administered after or during a meal to improve the pharmacokinetics of the formulation. In particular, administration of the formulation after or during a meal decreases the absorption of lactitol and reduces the AUC.
    Type: Grant
    Filed: May 12, 2017
    Date of Patent: October 20, 2020
    Inventors: Mark vB Cleveland, Robert M Raleigh, Russell W Pelham
  • Patent number: 7291324
    Abstract: Stimulant laxative in combination with an osmotic laxative produces safe and effective bowel and colon cleansing with a reduced volume of liquid input. Administering to a patient an oral stimulant laxative, such as bisacodyl, followed, after a biologically determined interval, by a reduced volume of a PEG in water solution cleanses the bowels and colon in preparation for diagnostic colonoscopy, without the profuse uncontrollable diarrhea that typically follows either ingestion of large volume isotonic ravages, or smaller volume hypertonic lavages.
    Type: Grant
    Filed: October 22, 2002
    Date of Patent: November 6, 2007
    Assignee: Braintree Laboratories Inc.
    Inventors: Edmund V. Dennett, Jr., Robert M. Raleigh, Jr., Mark V B. Cleveland, Russell W. Pelham
  • Patent number: 6875445
    Abstract: A composition for inhibiting gastrointestinal absorption of phosphorous in an individual. The composition includes a quantity of calcium acetate sufficient to bind the phosphorous in the gastrointestinal tract of the individual. The calcium acetate has a bulk density of between 0.50 kg/L and 0.80 kg/L and is dimensioned to form a caplet for fitting within a capsule in a manner that optimizes the volume of the capsule. Also provided is a method for administering the calcium acetate composition of the present invention to an individual to reduce phosphorous absorption by binding with the phosphorous in their gastrointestinal tract.
    Type: Grant
    Filed: October 24, 2002
    Date of Patent: April 5, 2005
    Assignee: Nabi Biopharmaceuticals
    Inventors: Edmund V. Dennett, Jr., Robert M. Raleigh, Jr., Bruce H. Aronson
  • Publication number: 20040191213
    Abstract: Stimulant laxative in combination with an osmotic laxative produces safe and effective bowel and colon cleansing with a reduced volume of liquid input. Administering to a patient an oral stimulant laxative, such as bisacodyl, followed, after a biologically determined interval, by a reduced volume of a PEG in water solution cleanses the bowels and colon in preparation for diagnostic colonoscopy, without the profuse uncontrollable diarrhea that typically follows either ingestion of large volume isotonic ravages, or smaller volume hypertonic ravages.
    Type: Application
    Filed: October 22, 2002
    Publication date: September 30, 2004
    Inventors: Russell W. Pelham, Vivian Caballero, Edmund V. Dennett, Bruce H. Aronson, Robert M. Raleigh, Mark vB. Cleveland
  • Patent number: 6576665
    Abstract: A composition for inhibiting gastrointestinal absorption of phosphorous in an individual. The composition includes a quantity of calcium acetate sufficient to bind the phosphorous in the gastrointestinal tract of the individual. The calcium acetate has a bulk density of between 0.50 kg/L and 0.80 kg/L and is dimensioned to form a caplet for fitting within a capsule in a manner that optimizes the volume of the capsule. Also provided is a method for administering the calcium acetate composition of the present invention to an individual to reduce phosphorous absorption by binding with the phosphorous in their gastrointestinal tract.
    Type: Grant
    Filed: April 3, 2001
    Date of Patent: June 10, 2003
    Assignee: Braintree Laboratories, Inc.
    Inventors: Edmund V. Dennett, Jr., Robert M. Raleigh, Jr., Bruce H. Aronson
  • Publication number: 20030050340
    Abstract: A composition for inhibiting gastrointestinal absorption of phosphorous in an individual. The composition includes a quantity of calcium acetate sufficient to bind the phosphorous in the gastrointestinal tract of the individual. The calcium acetate has a bulk density of between 0.50 kg/L and 0.80 kg/L and is dimensioned to form a caplet for fitting within a capsule in a manner that optimizes the volume of the capsule. Also provided is a method for administering the calcium acetate composition of the present invention to an individual to reduce phosphorous absorption by binding with the phosphorous in their gastrointestinal tract.
    Type: Application
    Filed: October 24, 2002
    Publication date: March 13, 2003
    Inventors: Edmund V. Dennett, Robert M. Raleigh, Bruce H. Aronson
  • Publication number: 20020173544
    Abstract: A composition for inhibiting gastrointestinal absorption of phosphorous in an individual dividual. The composition includes a quantity of calcium acetate sufficient to bind the phosphorous in the gastrointestinal tract of the individual. The calcium acetate has a bulk density of between 0.50 kg/L and 0.80 kg/L and is dimensioned to form a caplet for fitting within a capsule in a manner that optimizes the volume of the capsule. Also provided is a method for administering the calcium acetate composition of the present invention to an individual to reduce phosphorous absorption by binding with the phosphorous in their gastrointestinal tract.
    Type: Application
    Filed: April 3, 2001
    Publication date: November 21, 2002
    Inventors: Edmund V. Dennett, Robert M. Raleigh, Bruce H. Aronson